Co-occurrence of @entity148 and XXXX following @entity0 surgery and its impact on quality of life.

@entity1 @entity148 @entity0 @entity308
PURPOSE: Little is known about the prevalence of combined @entity148 and @entity308 (CADS) in @entity0 @entity1 . Purpose was to evaluate for differences in demographic and clinical characteristics and quality of life (QOL) prior to @entity0 surgery among @entity1 classified into one of four distinct @entity148 and/or @entity308 symptom groups. METHODS: A total of 335 @entity1 completed measures of @entity148 and @entity308 and QOL prior to and for 6 months following @entity0 surgery. Growth Mixture Modelling (GMM) was used to identify subgroups of @entity1 with distinct trajectories of @entity148 and @entity308 . These results were used to create four distinct @entity148 and/or @entity308 symptom groups. Differences in demographic, clinical, and symptom characteristics, among these groups were evaluated using analyses of variance and Chi square analyses. RESULTS: A total of 44.5% of @entity1 were categorized with CADS. @entity1 with CADS were younger, non-white, had lower performance status, received neoadjuvant or adjuvant chemotherapy, had greater difficulty dealing with their disease and treatment, and reported less support from others to meet their needs. These @entity1 had lower physical, psychological, social well-being, and total QOL scores. Higher levels of @entity148 with or without @entity308 were associated with increased fears of recurrence, hopelessness, uncertainty, loss of control, and a decrease in life satisfaction. CONCLUSIONS: Findings suggest that CADS occurs in a high percentage of @entity1 following @entity0 surgery and results in a poorer QOL. Assessments of @entity148 and @entity308 are warranted prior to surgery for @entity0 .
